Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice

Krystyna M. Wozniak, Kenichi Nomoto, Rena G. Lapidus, Ying Wu, Valentina Carozzi, Guido Cavaletti, Kazuhiro Hayakawa, Satoru Hosokawa, Murray J. Towle, Bruce A. Littlefield, Barbara S. Slusher

Research output: Contribution to journalArticlepeer-review

74 Scopus citations


Chemotherapy-induced neurotoxicity is a significant problem associated with successful treatment of many cancers. Tubulin is a well-established target of antineoplastic therapy; however, tubulin-targeting agents, such as paclitaxel and the newer epothilones, induce significant neurotoxicity. Eribulin mesylate, a novel microtubule-targeting analogue of the marine natural product halichondrin B, has recently shown antineoplastic activity, with relatively low incidence and severity of neuropathy, in metastatic breast cancer patients. The mechanism of chemotherapy-induced neuropathy is not well understood. One of the main underlying reasons is incomplete characterization of pathology of peripheral nerves from treated subjects, either from patients or preclinically from animals. The current study was conducted to directly compare, in mice, the neuropathy-inducing propensity of three drugs: paclitaxel, ixabepilone, and eribulin mesylate. Because these drugs have different potencies and pharmacokinetics, we compared them on the basis of a maximum tolerated dose (MTD). Effects of each drug on caudal and digital nerve conduction velocity, nerve amplitude, and sciatic nerve and dorsal root ganglion morphology at 0.25 x MTD, 0.5 x MTD, 0.75 x MTD, and MTD were compared. Paclitaxel and ixabepilone, at their respective MTDs, produced significant deficits in caudal nerve conduction velocity, caudal amplitude and digital nerve amplitudes, as well as moderate to severe degenerative pathologic changes in dorsal root ganglia and sciatic nerve. In contrast, eribulin mesylate produced no significant deleterious effects on any nerve conduction parameter measured and caused milder, less frequent effects on morphology. Overall, our findings indicate that eribulin mesylate induces less neuropathy in mice than paclitaxel or ixabepilone at equivalent MTD-based doses.

Original languageEnglish (US)
Pages (from-to)3952-3962
Number of pages11
JournalCancer Research
Issue number11
StatePublished - Jun 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice'. Together they form a unique fingerprint.

Cite this